Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the prostate~* Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy~* Detectable metastases~* ECOG performance status ≤2 (Performance status of 3 if due to bone pain)~* Any Gleason score~* Only one prior treatment with systemic chemotherapy~* No prior treatment with gene therapy~* No prior immunotherapy for prostate cancer~* Taxane naïve~* Experiencing cancer-related pain

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).